McLaughlin Asset Management Inc. Invests $552,000 in Merck & Co., Inc. $MRK

McLaughlin Asset Management Inc. purchased a new stake in Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 5,241 shares of the company’s stock, valued at approximately $552,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MRK. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at approximately $25,000. Prosperity Bancshares Inc bought a new stake in Merck & Co., Inc. in the fourth quarter worth $26,000. Abound Financial LLC purchased a new position in Merck & Co., Inc. during the fourth quarter worth $26,000. IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. during the fourth quarter valued at $31,000. Finally, High Note Wealth LLC grew its holdings in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on MRK. UBS Group increased their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Barclays initiated coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They issued an “overweight” rating and a $140.00 price objective on the stock. Royal Bank Of Canada reiterated an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research report on Monday, March 30th. JPMorgan Chase & Co. upped their price target on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a report on Monday, April 6th. Finally, Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $128.18.

Merck & Co., Inc. Price Performance

MRK opened at $114.04 on Friday. Merck & Co., Inc. has a 12-month low of $76.66 and a 12-month high of $125.14. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The business’s fifty day simple moving average is $116.12 and its 200-day simple moving average is $113.60. The company has a market capitalization of $281.65 billion, a price-to-earnings ratio of 32.12, a PEG ratio of 2.60 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period last year, the firm earned $2.22 earnings per share. The company’s quarterly revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is currently 95.77%.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The U.S. FDA approved an additional indication for CAPVAXIVE, Merck’s pneumococcal vaccine, expanding its use to children and adolescents ages 2 through 17 at increased risk for pneumococcal disease. The expanded label could support longer-term sales growth and reinforces Merck’s vaccine franchise. Article Title
• Neutral Sentiment: Merck also announced broader corporate activity around AI drug discovery with Protillion Biosciences and a global HPV awareness campaign, which may help pipeline development and brand visibility over time but are not immediate revenue drivers. Article Title
• Neutral Sentiment: A separate survey from Merck Animal Health highlighted unmet needs in treating canine allergic skin disease, suggesting future product opportunity, but it is a relatively small and less immediate catalyst for the stock. Article Title
• Negative Sentiment: Despite the FDA win, MRK has still been trading lower recently, reflecting broader weakness in the shares and suggesting investors may be waiting for more evidence that new and existing products can offset slower growth in other parts of the portfolio. Article Title

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.